Compounded is not generic
A generic drug has demonstrated bioequivalence to an approved product and has been through FDA review. There is currently no generic semaglutide or tirzepatide in the United States — both remain under patent.
A compounded drug is prepared by a pharmacy. It has not been through the FDA approval process, and the FDA does not verify its safety, effectiveness or quality before it reaches you. That is not an accusation of wrongdoing — compounding is legal and has legitimate clinical uses — but it is a materially different set of guarantees.
If a company's marketing lets you believe compounded means 'the same drug, cheaper', that is the misunderstanding they are relying on.
The two kinds of compounding pharmacy
503A pharmacies compound for an individual patient against an individual prescription. They are regulated primarily by state boards of pharmacy.
503B outsourcing facilities can compound in larger batches without patient-specific prescriptions, and register with and are inspected by the FDA. They are held to stricter manufacturing standards, though still not to the approval standard of a brand-name drug.
If you are going to use a compounded product, knowing which type of facility made it is a reasonable question to ask, and a provider who will not answer it is telling you something.
Why compounded GLP-1s were widely available — and why that changed
Federal law generally prohibits compounding a drug that is essentially a copy of a commercially available approved drug. There is an exception when the drug appears on the FDA's shortage list.
Semaglutide and tirzepatide were both in shortage for an extended period, which is what opened the door to mass compounding. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and set out enforcement timelines through 2025 after which compounding of essentially-copy versions should stop.
Some operators have continued selling compounded versions on the argument that a 'personalised' formulation — a different dose, or an added ingredient such as a vitamin — is not essentially a copy. The FDA has expressed concern about that reasoning. This remains a contested and shifting area, so verify the current position before you buy rather than trusting a marketing page.
The specific risks the FDA has flagged
Dosing errors. Compounded products often arrive in vials requiring you to draw a dose yourself, rather than in a pre-filled pen. The FDA has received reports of people taking many times their intended dose because of confusion between units, millilitres and milligrams.
Salt forms. Some products have been sold containing semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base in approved products, and their safety and effectiveness have not been established.
Unverified sourcing. Active ingredient sourced from facilities not registered with the FDA has turned up in this supply chain, including material of unknown provenance.
- Ask whether it is a 503A or 503B facility
- Ask for the exact active ingredient, including salt form
- Ask whether it ships as a pre-filled pen or a vial you draw from
- Ask for a certificate of analysis for the batch
Where the cost difference comes from
Compounded products are frequently a fraction of the brand-name cash price, and that is genuinely why people use them. But it is worth being precise about what the saving buys.
You are not paying less for the same guarantees. You are paying less because the product has not been through approval, the manufacturing standard may be lower, and the company's costs are lower as a result.
That may still be the right trade for you. It is a trade that should be made deliberately.
Manufacturer self-pay has narrowed the gap
Both manufacturers now run direct cash-pay channels for people without coverage — Eli Lilly through LillyDirect and Novo Nordisk through NovoCare — at prices substantially below historic list prices.
This has changed the arithmetic considerably. In some cases the brand-name self-pay price is now close enough to compounded pricing that the regulatory trade is much harder to justify. Compare the current numbers before assuming compounded is the cheap option.
What to ask a provider before you buy
Any legitimate provider will answer all of these plainly and in writing. Evasion on any of them is your answer.
- Is the medication FDA-approved, or compounded?
- If compounded, which pharmacy makes it and is it a 503A or 503B facility?
- What exactly is the active ingredient, including salt form?
- Does it arrive as a pre-filled pen or a vial I draw from myself?
- What is the total cost after any introductory period ends?
- What happens to my dose and my cost if I need to escalate?